Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;6(3):432-443.
doi: 10.21037/tau.2017.03.77.

A critical comparison of techniques for MRI-targeted biopsy of the prostate

Affiliations
Review

A critical comparison of techniques for MRI-targeted biopsy of the prostate

Francesco Giganti et al. Transl Androl Urol. 2017 Jun.

Abstract

MRI-targeted biopsy is a promising technique that offers an improved detection of clinically significant prostate cancer over standard non-targeted biopsy. It is established that prostate MRI is of use in both the primary and repeat biopsy setting for the detection of significant prostate cancer. There are three approaches to targeting biopsies to areas of interest seen on prostate MRI. They each rely on the acquisition and reporting of a diagnostic quality multi-parametric MRI scan used to identify areas of interest, and the subsequent use of those diagnostic quality images in combination with real-time images of the prostate during the biopsy procedure. The three techniques are: visual registration of the MRI images with a real-time ultrasound image; software-assisted fusion of the MRI images and the real-time ultrasound images, and in-bore biopsy, which requires registration of a diagnostic quality MRI scan with a real time interventional MRI image. In this paper we compare the three techniques and evaluate those studies where there is a direct comparison of more than one MRI-targeting technique. PubMed was searched from inception to November 2016 using the search terms (cognitive registration OR visual registration OR fusion biopsy OR in-bore biopsy OR targeted biopsy) AND (prostate cancer OR prostate adenocarcinoma OR prostate carcinoma OR prostatic carcinoma OR prostatic adenocarcinoma) AND (MRI OR NMR OR magnetic resonance imaging OR mpMRI OR multiparametric MRI). The initial search included 731 abstracts. Eleven full text papers directly compared two or more techniques of MRI-targeting, and were selected for inclusion. The detection of clinically significant prostate cancer varied from 0% to 93.3% for visual registration, 23.2% to 100% for software-assisted registration and 29% to 80% for in-bore biopsy. Detection rates for clinically significant cancer are dependent on the prevalence of cancer within the population biopsied, which in turn is determined by the selection criteria [biopsy naïve, previous negative biopsy, prostate specific antigen (PSA) selection criteria, presence of a lesion on MRI]. Cancer detection rates varied more between study populations than between biopsy approaches. Currently there is no consensus on which type of MRI-targeted biopsy performs better in a given setting. Although there have been studies supporting each of the three techniques, substantial differences in methodology and reporting the findings make it difficult to reliably compare their outcomes.

Keywords: Image-guided biopsy; magnetic resonance imaging; prostate; prostatic neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Hand drawn diagram made by the reporting radiologist that can be saved within the MRI file together with snapshots of the suspicious areas to be targeted. SV, seminal vesicles.
Figure 2
Figure 2
Flow diagram showing the outcome of the initial searches resulting in the full studies included in the review. MRI, magnetic resonance imaging.

References

    1. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-4; discussion 74-5. - PubMed
    1. European Association of Urology. Guidelines on Prostate Cancer. 2013. Available online: https://uroweb.org/wp-content/uploads/1607-Prostate-Cancer_LRV3.pdf
    1. Bjurlin MA, Taneja SS., et al. Standards for prostate biopsy. Curr Opin Urol 2014;24:155-61. 10.1097/MOU.0000000000000031 - DOI - PMC - PubMed
    1. Jin BS, Kang SH, Kim DY, et al. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter? Korean J Urol 2015;56:624-9. 10.4111/kju.2015.56.9.624 - DOI - PMC - PubMed
    1. Rosenkrantz AB, Verma S, Choyke P, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol 2016;196:1613-8. 10.1016/j.juro.2016.06.079 - DOI - PMC - PubMed